Shaily Engineering Plastics announces regulatory approvals for its ShailyPen Neo™ device incorporated in generic Semaglutide injection.
The spring-driven pen injector platform received USFDA tentative approval, Health Canada compliance, and Indian CDSCO approval.
The combination product is commercially available in India since March 2026 and recently launched in Canada.
Shaily designed, developed, and manufactures the device components for this high-performance drug delivery system.